Gastrointestinal Cancer | Topics

IMU-131 Plus SOC Improves OS Vs SOC Alone in Advanced/Metastatic Gastric or GEJ Cancer
June 28, 2022

Results from the phase 2 HERIZON study identified improved overall survival for patients treated with IMU-131 plus standard of care vs standard of care alone in advanced or metastatic gastric or gastroesophageal junction cancer.

68Ga-RM26 PET/CT Imaging Demonstrates Promise in Gastrointestinal Stromal Tumors
June 18, 2022

Patients with gastrointestinal stromal tumors may benefit from 68GA-RM26 PET/CT vs 18F-FDG, according to findings presented at the 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting.

Shubham Pant, MD, Highlights Outcomes With Erdafitinib in Gastrointestinal Cancers
June 13, 2022

Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal and other solid tumor malignancies.

Dostarlimab Yields Clinical Complete Response in Entire Treated Population in dMMR Advanced Rectal Cancer
June 08, 2022

A 100% clinical complete response rate was observed when patients with stage II/III mismatch repair-deficient locally advanced rectal cancer were treated with dostarlimab.

CLDN18.2-Directed CAR T-cell Therapy Effective, Safe in Gastrointestinal Cancers
June 05, 2022

A Claudin18.2–specific CAR T-cell therapy has shown promise in the treatment of patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma whose disease expresses the marker.

Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Colleagues Discuss GOZILA Platform for CRC
May 17, 2022

Tanios Bekaii-Saab, MD, details the GOZILA platform for colorectal cancer with experts Kristen Ciombor, MD, MSCI, and John Strickler, MD.

Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, Talks COLOMATE Platform in CRC With Experts
May 10, 2022

Tanios Bekaii-Saab, MD, sits with Kristen Ciombor, MD, MSCI, and John Strickler, MD, to examine the COLOMATE platform for patients with colorectal cancer.

Sam Klempner, MD, Looks at Broad Use of ctDNA in Oncology
May 05, 2022

Sam Klempner, MD, spoke about how clinicians exploring use of ctDNA in gastrointestinal cancers may inform their research with results from other tumor types.

FDA Grants Priority Review to Durvalumab Plus Chemo in Locally Advanced or Metastatic Biliary Tract Cancer
May 04, 2022

The results of the phase 3 TOPAZ-1 trial led to the priority review of durvalumab plus chemotherapy in patients with locally advanced biliary tract cancer.

CMG901 Granted Fast Track Designation by FDA in Unresectable or Metastatic Relapsed/Refractory Gastric and GEJ Cancer
April 27, 2022

Patients with unresectable or metastatic gastric or gastroesophageal junction cancer that is relapsed/refractory following other approved therapies may benefit from treatment with single-agent CMG901, which was granted fast track designation by the FDA.